Press release
PARP Inhibitors Market Expansion Fueled by Combination Therapies and Innovative Oncology R&D Pipelines
PARP Inhibitors Market
Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1169
Poly (ADP-ribose) polymerase (PARP) inhibitors constitute a class of precision therapeutics that target a family of 17 enzymes responsible for synthesizing poly (ADP-ribose) chains. These chains are covalently linked to specific proteins involved in repairing single-strand DNA breaks, a critical mechanism for maintaining genomic stability in response to damage caused by ultraviolet and ionizing radiation, chemotherapeutic agents, and environmental toxins.
By inhibiting PARP enzyme activity, these therapies disrupt cellular DNA repair processes, leading to the accumulation of DNA damage and triggering cell death, particularly in cancer cells deficient in alternative DNA repair pathways.
The anticipated global rise in the elderly population-who exhibit higher susceptibility to chronic diseases, including cancer-is expected to drive significant demand for PARP inhibitors. Projections indicate that the population aged 65 and older will approximately double in the coming years, further enhancing the market potential.
Nevertheless, market expansion may face challenges due to the development of resistance to PARP inhibitors and their limited efficacy in specific patient subgroups. These factors underscore the necessity for continued investment in research and development aimed at improving clinical outcomes and expanding the therapeutic applicability of PARP inhibitors across diverse disease indications.
List of Prominent Players in the PARP Inhibitors Market:
• Johnson & Johnson Services, Inc.
• Merck KGaA
• GSK plc.
• Pfizer Inc.
• AbbVie Inc.
• Teva Pharmaceutical Industries Ltd.
• Artios Pharma
• Genentech, Inc.
• Karyopharm Therapeutics Inc.
• Repare Therapeutics Inc
• ONO PHARMACEUTICAL CO., LTD
• Jiangsu Hengrui Pharma Co., Ltd.
• Bristol-Myers Squibb Co
• AstraZeneca plc
• Checkpoint Therapeutics, Inc.
• Eisai Co., Ltd.
• IMPACT Therapeutics
• JEIL PHARMA CO., LTD.
• Kyowa Kirin Co., Ltd
• SyntheX
Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-02
Market Dynamics
Drivers:
The growth of the PARP inhibitors market is primarily driven by the rising global incidence of prostate cancer. As reported by the World Cancer Research Fund, prostate cancer ranks as the second most commonly diagnosed cancer in men and the fourth most prevalent cancer globally. The increasing adoption of Olaparib as a first-line therapy for advanced prostate cancer is expected to significantly contribute to market expansion within this segment. Furthermore, the growing application of PARP inhibitors in combination with other breast cancer treatments-such as chemotherapy and radiation therapy targeting DNA damage induced by ultraviolet (UV) radiation-is anticipated to further accelerate market growth.
Challenges:
The market faces challenges arising from intensified competition among pharmaceutical companies developing PARP inhibitors, which may result in market saturation, reduced pricing flexibility, and difficulties in differentiating products. Additionally, the substantial costs associated with research, development, and clinical trials pose significant financial risks. These high investment requirements may act as barriers to new market entrants and influence pricing strategies, thereby impacting overall market dynamics and growth prospects.
Regional Trends:
North America is projected to hold a dominant share of the global PARP inhibitors market, supported by a strong compound annual growth rate (CAGR) over the forecast period. The integration of genomic testing into standard oncology practices, enabled by advanced healthcare infrastructure and heightened clinical awareness, has facilitated more widespread identification of genetic mutations, promoting the adoption of targeted therapies such as PARP inhibitors.
In Europe, market growth is supported by strategic collaborations between academic institutions and pharmaceutical companies. These partnerships aim to accelerate clinical research, expand treatment indications, and enhance the therapeutic application of PARP inhibitors across multiple cancer types.
Recent Developments:
• In 2023, an acquisition of CinCor Pharma, Inc. was announced by AstraZeneca in order to enhance its cardiorenal pipeline. CinCor's candidate medication, baxdrostat (CIN-107), an aldosterone synthase inhibitor (ASI), is being integrated into this strategic approach to address resistant to treatment hypertension by reducing blood pressure.
• In 2022, AstraZeneca and G42 Healthcare have formed a strategic partnership to produce pharmaceutical products in Abu Dhabi. The objective of this partnership is to improve the local manufacturing capabilities and facilitate the production of essential pharmaceuticals, thereby increasing the accessibility of healthcare in the region.
• In 2022, Helio Genomics, in collaboration with Fulgent Genetics, has obtained a new Category I CPT code from the AMA for HelioLiver, thereby facilitating the widespread implementation of advanced surveillance tests for liver cancer in the United States. This accomplishment broadens the company's market presence and product line.
Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/1169
Segmentation of PARP Inhibitors Market-
By Product-
• Niraparib (Zejula)
• Olaparib (Lynparza)
• Rucaparib (Rubraca)
• Talazoparib (Talzenna)
• Veliparib
• Other Pipeline Drugs
By Indication-
• Ovarian Cancer
• Breast cancer
• Prostate and Pancreatic Cancer
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa
Read Overview Report- https://www.insightaceanalytic.com/report/global-parp-inhibitors-market-/1169
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release PARP Inhibitors Market Expansion Fueled by Combination Therapies and Innovative Oncology R&D Pipelines here
News-ID: 4151646 • Views: …
More Releases from Insightace Analytic Pvt Ltd.
4PL Logistics Market Revenue Report with Forecast to 2034
"4PL Logistics Market" in terms of revenue was estimated to be worth $59.6 Billion in 2024 and is poised to reach $133.3 Billion by 2034, growing at a CAGR of 8.5% from 2025 to 2034 according to a new report by InsightAce Analytic.
Get Free Sample Report @
https://www.insightaceanalytic.com/request-sample/1609
Latest Drivers Restraint and Opportunities Market Snapshot:
Key factors influencing the global 4PL Logistics Market are:
• Rapid growth of automotive the…
Heavy-Duty Autonomous Vehicle Market Exclusive Trends Analysis with Forecast to …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Heavy-Duty Autonomous Vehicle Market- (By Application (Logistics, Public Transportation, Construction and Mining, Others), By Propulsion Type (Internal Combustion Engine Vehicles, Electric Vehicles), By Vehicle Type (Heavy Trucks, Heavy Buses, Roboshuttles), By Level of Autonomy (Fully Autonomous Vehicles, Semi-Autonomous Vehicles), By Sensor Type (LiDAR, RADAR, Camera, Others)) Trends, Industry Competition Analysis, Revenue and Forecast To 2034."
According…
E-Commerce Logistics Market Exclusive Report with Detailed Study Analysis
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global E-Commerce Logistics Market Size, Share & Trends Analysis Report By Service Type (Transportation And Warehousing) And Operational Area (International And Domestic)- Market Outlook And Industry Analysis 2034"
The global e-commerce logistics market is estimated to reach over USD 5340.2 billion by 2034, exhibiting a CAGR of 26.4% during the forecast period.
Request For Free Sample Pages:…
E-bikes Market Exclusive Report on the Latest Revenue and Future Scope
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global E-bikes Market Size, Share & Trends Analysis Report By Class (Class-I, Class-II, Class-III), Speed (Up to 25km/h, 25-45 km/h), Battery Type (Lithium-ion, Lithium-ion Polymer, Lead Acid), Mode (Pedal Assist, Throttle), Component (batteries, electric motors, frames with forks, wheels, crank gears, brake systems and motor controllers) , Motor Type (hub and mid), Usage (mountain, trekking, city/urban,…
More Releases for PARP
PARP Inhibitor Biomarkers Market Size to Expand Lucratively by 2034
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global PARP Inhibitor Biomarkers Market - (By Product (Kits, Assays), By Services (BRCA 1 & 2 Testing, HRD Testing, HRR Testing, Others), By Application (Breast Cancer, Ovarian Cancer, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
According to the latest research by InsightAce Analytic, the Global PARP Inhibitor Biomarkers Market is valued at US$ 879.8…
Parp Inhibitors Market Driven by Demand for Immersive Technologies Across Indust …
Global Parp Inhibitors Market Impact of AI and Automation
The PARP inhibitors market has seen remarkable growth in recent years, primarily driven by advances in cancer treatment and the increasing prevalence of cancer globally. These inhibitors, which block the enzyme poly (ADP-ribose) polymerase (PARP), are proving to be highly effective in targeting specific cancer cells, especially in cancers with DNA repair deficiencies like ovarian, breast, and prostate cancers. The approval of…
China Market Analysis of PARP Inhibitors: Growth Opportunities
Global PARP Inhibitors Market: Introduction
A PARP (poly ADP-ribose polymerase) inhibitor is a substance that blocks PARP enzyme in the cell. DNA damage occurs during cancer. Blocking of PARP helps the cancer cells in repairing their damaged part of DNA.
Read Report Overview - https://www.transparencymarketresearch.com/parp-inhibitors-market.html
Global PARP Inhibitors Market: Competition Landscape
Key players operating in the global PARP inhibitors market are AstraZeneca, Tesaro, AbbVie Inc., Medivation, and Clovis Oncology. The global market is…
PARP Inhibitors Market Trends and Segments
Cancer is the leading cause of death worldwide with 8.2 million cancer related deaths in 2012 estimated by World Health Organization (WHO). PARP Inhibitors are the drugs, which inhibit the enzyme called poly ADP ribose polymerase (PARP). PARP inhibitors developed for treating several diseases, the most important one is cancer. As several types of cancers rely on PARP than regular cells, which makes it attractive target for treating cancers. These…
PARP Inhibitors Market Dynamics, Segments, Size and Demand, 2017 - 2027
Cancer is the leading cause of death worldwide with 8.2 million cancer related deaths in 2012 estimated by World Health Organization (WHO). PARP Inhibitors are the drugs, which inhibit the enzyme called poly ADP ribose polymerase (PARP). PARP inhibitors developed for treating several diseases, the most important one is cancer. As several types of cancers rely on PARP than regular cells, which makes it attractive target for treating cancers. These…
Global PARP Inhibitor Market: Size, Trends And Forecasts (2016-2020)
Scope of the Report
The report titled Global PARP Inhibitor Market: Size, Trends and Forecasts (2016-2020) provides an in-depth analysis of the global PARP inhibitor market with detailed analysis of market size on the basis of value along with the comprehensive examination of each of the segments of the market, namely, Lynparza, Niraparib, Rucaparib, Talazoparib and Veliparib.
The report analyses the global Lynparza market in detail along with the regional analysis as…
